全文获取类型
收费全文 | 186篇 |
免费 | 9篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 14篇 |
妇产科学 | 8篇 |
基础医学 | 10篇 |
口腔科学 | 2篇 |
临床医学 | 8篇 |
内科学 | 52篇 |
皮肤病学 | 5篇 |
神经病学 | 4篇 |
特种医学 | 2篇 |
外科学 | 12篇 |
综合类 | 4篇 |
预防医学 | 33篇 |
眼科学 | 9篇 |
药学 | 17篇 |
肿瘤学 | 17篇 |
出版年
2022年 | 6篇 |
2021年 | 11篇 |
2020年 | 6篇 |
2019年 | 2篇 |
2018年 | 7篇 |
2017年 | 4篇 |
2016年 | 8篇 |
2015年 | 5篇 |
2014年 | 12篇 |
2013年 | 18篇 |
2012年 | 13篇 |
2011年 | 18篇 |
2010年 | 6篇 |
2009年 | 9篇 |
2008年 | 13篇 |
2007年 | 9篇 |
2006年 | 7篇 |
2005年 | 7篇 |
2004年 | 3篇 |
2003年 | 4篇 |
2002年 | 3篇 |
2001年 | 2篇 |
2000年 | 3篇 |
1998年 | 1篇 |
1996年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1989年 | 3篇 |
1988年 | 1篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1979年 | 1篇 |
1976年 | 3篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1968年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有198条查询结果,搜索用时 31 毫秒
1.
2.
3.
Shailender Swaminathan Vincent Mor Rajnish Mehrotra Amal N Trivedi 《Health services research》2015,50(3):790-808
ObjectiveIn 2011, the Centers for Medicare and Medicaid Services (CMS) replaced fee-for-service reimbursement for erythropoiesis stimulating agents (ESAs) with a fixed-sum bundled payment for all dialysis-related care and pay-for-performance incentives to discourage maintaining patients'' hematocrits above 36 percent. We examined the impact of the new payment policy on the use of ESAs.ConclusionsCMS''s payment reform for dialysis care reduced the use of ESAs in patients who may not benefit from these agents. 相似文献
4.
6.
7.
Tumor lysis syndrome in extensive-stage small-cell lung cancer 总被引:2,自引:0,他引:2
Tumor lysis syndrome is a constellation of metabolic complications that occurs in the setting of treatment of hematologic malignancies. On occasion, it has been reported to occur after therapy for solid tumors associated with large tumor burdens and aggressive therapy. We herein report the rare occurrence of acute tumor lysis syndrome in a woman with extensive-stage small-cell lung cancer after cytotoxic therapy. 相似文献
8.
9.
Carnitine is necessary for the translocation of fatty acids into the mitochondria, and the relative concentration of carnitine and acylcarnitine in the serum are known to reflect metabolic states. A survey of serum carnitine concentrations was made in 54 cancer and 81 noncancer patients for the purpose of determining the carnitine profile. The total carnitine, nonesterified carnitine, and acid-insoluble acylcarnitine concentrations of cancer patients were similar to noncancer patients and within the normal range; however, the acid-soluble acylcarnitine concentration was significantly lower in cancer patients than in controls (6.7 vs 11.5 nmol/ml). When percentages and ratios were calculated for the relative proportions of acylcarnitines, large variations were found to occur among cancer types. The acylcarnitine ratio (the sum of acid-soluble and acid-insoluble acylcarnitine divided by nonesterified carnitine) ranged from 0.17 in leukemia to 0.30 in breast cancer cases. Since the acylcarnitine concentration and ratio are reflective of the metabolic state, the depressed acylcarnitine ratio in cancer patients may be due to decreased production, increased utilization, or increased excretion of acid-soluble acylcarnitine. Elevated concentrations of nonesterified carnitine and total carnitine were observed in two patients, and some of the lowest acylcarnitine concentrations and ratios were observed in advanced cancer cases. The therapeutic regimen and/or the neoplastic process itself may be responsible for the observed differences in the serum carnitine profile. 相似文献
10.